After a letter from Democratic congressmen questioned the pricing of Gilead's (GILD) HCV treatment, Sovaldi, RW Baird believes that the company can answer the questions regarding the drug's value. The firm thinks that drugs expected to be offered by Gilead in the future will be even more defensible. Meanwhile, after reviewing abstracts recently, RW Baird believes that the most important players in the HCV space remain Gilead and AbbVie (ABBV), followed by Bristol-Myers Squibb (BMY) and Merck (MRK). RW Baird keeps an Outperform rating on Gilead.
- Health Care Industry